PureTech Health (LON:PRTC) Shares Up 14.2% – Still a Buy?

Shares of PureTech Health plc (LON:PRTC) shot up 14.2% during trading on Saturday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). 9,013,305 shares changed hands during mid-day trading, an increase of 1,053% from the average session volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Stock Performance

The firm has a market cap of £293.65 million, a price-to-earnings ratio of 714.71 and a beta of 1.02. The stock has a 50 day moving average of GBX 129.46 and a 200 day moving average of GBX 129.72. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82.

Insider Buying and Selling

In other news, insider Bharatt Chowrira acquired 167,739 shares of the stock in a transaction dated Thursday, July 3rd. The stock was bought at an average price of GBX 1 per share, with a total value of £1,677.39. Insiders own 13.13% of the company’s stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.